TickerFactsScreenerDevelopers

Adaptimmune Therapeutics PLC (ADAPY) — Operating Cash Flow

Annual figures by fiscal year, from SEC filings.

2015: -$29.67M2016: -$48.17M2017: -$54.31M2018: -$104.39M2019: -$112.51M2020: -$53.59M2021: $10.73M2022: -$141.77M2023: -$140.88M2024: -$73.21M-$73.21M
2015Operating Cash Flow (USD)2024
Fiscal YearOperating Cash FlowChange YoY
2024-$73.21M+48.0%
2023-$140.88M+0.6%
2022-$141.77M-1421.4%
2021$10.73M+120.0%
2020-$53.59M+52.4%
2019-$112.51M-7.8%
2018-$104.39M-92.2%
2017-$54.31M-12.8%
2016-$48.17M-62.4%
2015-$29.67M—